**Quantities of Tirzepatide (Mounjaro®)**

**Tirzepatide multi-dose pre-filled KwikPens (Mounjaro®) were recently approved by LSCMMG for the management of Type 2 Diabetes in line with NICE TA9241 and criteria agreed locally by specialists.**

* It has a GREEN restricted RAG rating and valuable information such as which patients are most suitable, monitoring requirements, discontinuation criteria and deprescribing of other hypoglycaemic agents can be found at [https://www.lancsmmg.nhs.uk/medicines-library/tirzepatide-for-type-2-diabetes/#gsc.tab=0](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.lancsmmg.nhs.uk%2Fmedicines-library%2Ftirzepatide-for-type-2-diabetes%2F%23gsc.tab%3D0&data=05%7C02%7Cvbirchall%40nhs.net%7C22e35417a3944dc1decf08dcc33e5b01%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638599919777449653%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=Wcs9rEXas30ZxLpqFUej%2B4BPyph5BWnQaQYdYnBhdNo%3D&reserved=0)
* In addition, there is a useful LSCMMG position statement [https://www.lancsmmg.nhs.uk/media/1866/tirzepatide-for-type-2-diabetes-position-statement-approved-mar24.pdf](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.lancsmmg.nhs.uk%2Fmedia%2F1866%2Ftirzepatide-for-type-2-diabetes-position-statement-approved-mar24.pdf&data=05%7C02%7Cvbirchall%40nhs.net%7C22e35417a3944dc1decf08dcc33e5b01%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638599919777456958%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=atXrRbxtn4p%2FyRBoJahUwleSJk2RGTKf8WEHGToU0Cc%3D&reserved=0)

**Each tirzepatide multi-dose pre-filled KwikPen (Mounjaro®) contains four x 0.6ml fixed doses, one dose to be administered weekly, after which the pen should be disposed of.**

* **Only one pen should be prescribed every four weeks.** Prescribing reports indicate that in some instances four pens per month are being prescribed rather than one pen.
* Each pen costs £92 - £122 depending on strength.
* There are six available strengths of tirzepatide pre-filled pen: 2.5mg/0.6ml, 5mg/0.6ml, 7.5mg/0.6ml, 10mg/0.6ml, 12.5mg/0.6ml and 15mg/0.6ml.
* The starting dose of tirzepatide is 2.5 mg once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly. If needed, dose increases can be made in 2.5 mg increments after a minimum of 4 weeks on the current dose. The maximum dose is 15 mg once weekly.2 When titrating the dose, prescribe the next available strength of pen.

**Please ensure all clinicians who manage and/or prescribe medication for patients with Type 2 diabetes mellitus are aware of this information and that patients read the patient information leaflet and instructions for use guide in the useful resources section below.**

**Reference**:

1. NICE Tirzepatide for Treating Type 2 Diabetes Technology Appraisal (TA924) accessed 12/9/24 at this link <https://www.nice.org.uk/guidance/ta924/chapter/1-Recommendations>
2. Summary of Product Characteristics (SPC) accessed 12/9/24 at this link <https://www.medicines.org.uk/emc/product/15481/smpc>

**Useful Resources:**

**Patient information leaflet** accessed 12/9/24 at this link [https://www.medicines.org.uk/emc/files/pil.15484.pdf](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Ffiles%2Fpil.15484.pdf&data=05%7C02%7Cvbirchall%40nhs.net%7C22e35417a3944dc1decf08dcc33e5b01%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638599919777428812%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=dRchNlZxz%2BETv2Oie659YC42LEGw9Njnkz8GZldjMCQ%3D&reserved=0)

**Instructions for use guide** which contains information on how to inject the medication accessed 12/9/24 at this link [https://www.medicines.org.uk/emc/files/usermanual.15484.pdf](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Ffiles%2Fusermanual.15484.pdf&data=05%7C02%7Cvbirchall%40nhs.net%7C22e35417a3944dc1decf08dcc33e5b01%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638599919777441501%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=lcLpGz%2FYrQJe0gmSPvjmUAquHEFTn87xP%2Bpclfbniis%3D&reserved=0)

**UK Medicines Information regarding short supplies of GLP-1 receptor agonists** - requires login details – accessed 12/9/24 at this link

<https://www.sps.nhs.uk/articles/prescribing-available-glp-1-receptor-agonists/>